Display options
Cite
Sonawane YA, Zhu Y, Garrison JC, et al. Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors. ACS Med Chem Lett. 2017;8(11):1183-1187doi: 10.1021/acsmedchemlett.7b00358.
Sonawane, Y. A., Zhu, Y., Garrison, J. C., Ezell, E. L., Zahid, M., Cheng, X., & Natarajan, A. (2017). Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors. ACS medicinal chemistry letters, 8(11), 1183-1187. https://doi.org/10.1021/acsmedchemlett.7b00358
Sonawane, Yogesh A, et al. "Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors." ACS medicinal chemistry letters vol. 8,11 (2017): 1183-1187. doi: https://doi.org/10.1021/acsmedchemlett.7b00358
Sonawane YA, Zhu Y, Garrison JC, Ezell EL, Zahid M, Cheng X, Natarajan A. Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors. ACS Med Chem Lett. 2017 Oct 02;8(11):1183-1187. doi: 10.1021/acsmedchemlett.7b00358. eCollection 2017 Nov 09. PMID: 29375750; PMCID: PMC5774307.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2017 Oct 02;8(11):1183-1187. doi: 10.1021/acsmedchemlett.7b00358. eCollection 2017 Nov 09.

Structure-Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors.

ACS medicinal chemistry letters

Yogesh A Sonawane, Yingmin Zhu, Jered C Garrison, Edward L Ezell, Muhammad Zahid, Xiaodong Cheng, Amarnath Natarajan

Affiliations

  1. Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, Departments of Pharmaceutical Sciences, Environmental, Agricultural and Occupational Health, and Genetics Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska 68022, United States.
  2. Department of Integrative Biology and Pharmacology and Texas Therapeutics Institute, University of Texas Health Science Center, Houston, Texas 77030, United States.

PMID: 29375750 PMCID: PMC5774307 DOI: 10.1021/acsmedchemlett.7b00358

Abstract

EPAC proteins are therapeutic targets for the potential treatment of cardiac hypertrophy and cancer metastasis. Several laboratories use a tetrahydroquinoline analog, CE3F4, to dissect the role of EPAC1 in various disease states. Here, we report SAR studies with tetrahydroquinoline analogs that explore various functional groups. The most potent EPAC inhibitor

Conflict of interest statement

The authors declare no competing financial interest.

References

  1. Sci Rep. 2015 Mar 20;5:9344 - PubMed
  2. Cardiovasc Res. 2015 Jan 1;105(1):55-64 - PubMed
  3. Pharmacol Rev. 2013 Feb 27;65(2):670-709 - PubMed
  4. Genes Dev. 2000 Oct 1;14(19):2410-34 - PubMed
  5. Chem Rev. 2011 Nov 9;111(11):7157-259 - PubMed
  6. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18613-8 - PubMed
  7. Cell Signal. 2008 Jan;20(1):10-20 - PubMed
  8. Mol Pharmacol. 2013 Jan;83(1):122-8 - PubMed
  9. Biochem Biophys Res Commun. 2013 Oct 25;440(3):443-8 - PubMed
  10. Br J Cancer. 2009 Dec 15;101(12):2038-42 - PubMed
  11. J Med Chem. 2014 May 8;57(9):3651-65 - PubMed
  12. J Org Chem. 2012 Jun 1;77(11):5198-202 - PubMed
  13. Mol Cell Biochem. 2017 Jun;430(1-2):115-125 - PubMed
  14. PLoS One. 2012;7(1):e30441 - PubMed
  15. Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):651-62 - PubMed
  16. J Am Chem Soc. 2001 Mar 7;123(9):2038-46 - PubMed
  17. Br J Pharmacol. 2010 Jan 1;159(2):265-84 - PubMed
  18. Pancreas. 2008 Jul;37(1):102-3 - PubMed
  19. Magn Reson Chem. 2013 Feb;51(2):82-8 - PubMed
  20. J Biol Chem. 2012 Dec 28;287(53):44192-202 - PubMed

Publication Types

Grant support